Home Administration of CVD 103-HgR: A Live Attenuated Oral Cholera Vaccine

被引:0
|
作者
Duffin, Ryan Paul [1 ]
Delbuono, Michael [1 ]
Chew, Lawrence [1 ]
Johnstone, James [1 ]
Nieden, Volker [1 ]
Schwarz, Pascal [1 ]
Shabram, Paul [1 ]
Patel, Amish A. [1 ]
机构
[1] Emergent BioSolut, 400 Profess Dr,Suite 400, Gaithersburg, MD 20879 USA
来源
关键词
PRODUCT ATTRIBUTES;
D O I
10.4269/ajtmh.20-1223
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Vaccination is a well-established means for prevention and spread of disease in people traveling abroad. Although vaccines to diseases such as cholera are recommended by world health agencies, they are seldom required even when traveling to endemic regions. Consequences of noncompliance can affect traveler's health and spread diseases to new regions, as occurred in Haiti in 2010 when United Nations peacekeepers from Nepal, where a cholera outbreak was underway, introduced the disease to the region. Steps to increase vaccine recommendation compliance should therefore be an integral part of vaccine development. PXVX0200 contains Center for Vaccine Development 103HgR live, attenuated recombinant Vibrio cholerae vaccine strain, and is indicated for single-dose immunization against the bacteria that causes cholera. It is supplied as one buffer and one active component packet to be mixed into water and ingested. Administration instructions are designed to be "user friendly" with flexibility for self-administration, thus promoting compliance. Studies to support self-administration were conducted to cover stability of the vaccine outside of normal storage conditions, potency in case of misadministration, and disposal procedures to minimize environmental impact. The principal findings showed that the stability of vaccine was maintained under conditions allowing for transport times and temperature conditions as well as when misadministration errors were made. Finally, the vaccine was effectively neutralized with hot water and soap to prevent bacterial environmental contamination in the event of an accidental spill. The conclusion is that PXVX0200 oral vaccine is stable, easy to formulate and dispose of, and is amenable to self administration.
引用
收藏
页码:1232 / 1240
页数:9
相关论文
共 50 条
  • [1] Development of Pediatric Dosage Preparation for CVD 103-HgR Live Oral Cholera Vaccine
    Duffin, R. Paul
    Delbuono, Michael
    Nishioka, Kylie
    Shabram, Paul
    Patel, Amish A.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2022, 107 (02): : 388 - 392
  • [2] Update on CVD 103-HgR single-dose, live oral cholera vaccine
    McCarty, James
    Bedell, Lisa
    De Lame, Paul-Andre
    Cassie, David
    Lock, Michael
    Bennett, Sean
    Haney, Douglas
    [J]. EXPERT REVIEW OF VACCINES, 2022, 21 (01) : 9 - 23
  • [3] PaxVax CVD 103-HgR single-dose live oral cholera vaccine
    Levine, Myron M.
    Chen, Wilbur H.
    Kaper, James B.
    Lock, Michael
    Danzig, Lisa
    Gurwith, Marc
    [J]. EXPERT REVIEW OF VACCINES, 2017, 16 (03) : 197 - 213
  • [4] Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR
    Herzog, Christian
    [J]. TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2016, 14 (04) : 373 - 377
  • [5] Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR
    Cooper, PJ
    Chico, ME
    Losonsky, G
    Sandoval, C
    Espinel, I
    Sridhara, R
    Aguilar, M
    Guevara, A
    Guderian, RH
    Levine, MM
    Griffin, GE
    Nutman, TB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (04): : 1199 - 1206
  • [6] CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe
    R. Paul Duffin
    Michael Delbuono
    Kylie Nishioka
    Paul Shabram
    Amish A. Patel
    [J]. Scientific Reports, 11
  • [7] CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe
    Duffin, R. Paul
    Delbuono, Michael
    Nishioka, Kylie
    Shabram, Paul
    Patel, Amish A.
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [8] Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States
    McCarty, James M.
    Cassie, David
    Bedell, Lisa
    [J]. VACCINE, 2023, 41 (17) : 2739 - 2742
  • [9] Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers
    Lagos, R
    San Martin, O
    Wasserman, SS
    Prado, V
    Losonsky, GA
    Bustamante, C
    Levine, MM
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (07) : 624 - 630
  • [10] CVD 103-HgR vaccine for travelers
    Wong, Karen K.
    Mahon, Barbara E.
    Reingold, Arthur
    [J]. TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2016, 14 (06) : 632 - 633